Who
David S. Grayzel
Director
Company insider
Files Form 4 as: Director, Q32 Bio; Director, Jade Biosciences; Director, Surface Oncology.
In numbers
- Trades disclosed
- 42
- Buys
- 2
- Sells
- 3
- Bought
- $9.0M
- Sold
- $44.9M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 23 Apr 2018
- Last trade
- 12 Jun 2026
- Last filed
- 21 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 21 Jul 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,826 at $0.00 | filing |
| 12 Jun 2026filed 21 Jul 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,826 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —9,810 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —9,810 at $0.00 | filing |
| 15 Jan 2026filed 30 Jan 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | $45K16,363 at $2.75 | filing |
| 15 Jan 2026filed 30 Jan 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | $45K16,363 at $2.75 | filing |
| 23 Oct 2025filed 27 Oct 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —53,521 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —12,767 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —12,767 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —2,569 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —2,569 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —18,595 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —18,595 at $0.00 | filing |
| 15 Jan 2025filed 26 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —18,595 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 9 Apr 2024filed 11 Apr 2024 | JBIO Jade BiosciencesBiotechnology | SEC FORM 4 Sold | $334K11,882 at $28.15 | filing |
| 1 Apr 2024filed 14 Aug 2024 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | $34K2,569 at $13.42 | filing |
| 25 Mar 2024filed 27 Mar 2024 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —12,767 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | $43K3,186 at $13.49 | filing |
| 8 Sep 2023filed 8 Sep 2023 | Surface Oncology | SEC FORM 4 Code D | —2,945,453 | filing |
News
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026JBIO · manilatimes.net · 21 Oct 2026
0 headlines in the last 90 days name David S. Grayzel; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.